The use of intralaboratory and external quality control of immunohistochemical studies to improve the detection of estrogen and progesterone receptors

Kushnarev V.A.; Kudaibergenova A.G.; Zavalishina L.E.

doi:https://doi.org/10.17116/patol2021830215

Kushnarev V.A.

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia

Kudaibergenova A.G.

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-0677-7991

The use of intralaboratory and external quality control of immunohistochemical studies to improve the detection of estrogen and progesterone receptors

Authors:

Kushnarev V.A., Kudaibergenova A.G., Zavalishina L.E.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2021;83(2): 5‑9

DOI: 10.17116/patol2021830215

Read: 4005 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kushnarev VA, Kudaibergenova AG, Zavalishina LE. The use of intralaboratory and external quality control of immunohistochemical studies to improve the detection of estrogen and progesterone receptors. Russian Journal of Archive of Pathology. 2021;83(2):5‑9. (In Russ.)
https://doi.org/10.17116/patol2021830215

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Immunohistochemical study of breast cancer has been practiced for several decades; however, the standardization of this process has not yet been achieved, despite substantial advances in methodology. The paper presents practical guidelines and standards for testing breast carcinomas, which can be used as day-to-day control of the work of an immunohistochemistry laboratory. It considers the concept of external quality control in the immunohistochemical detection of estrogen (ER) and progesterone (PR) receptors, as well as the problems of harmonization in the immunohistochemical analysis of breast carcinomas, by using the nuclear biomarkers, such as ER and PR, as an example. The agreed standard-based external control in determining the optimal result may yield reproducible data for use in clinical practice.

Keywords:

external quality control

immunohistochemistry

breast cancer

estrogen receptors

progesterone receptors

Authors:

Kushnarev V.A.

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia

Kudaibergenova A.G.

N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia

Zavalishina L.E.

Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-0677-7991

Received:

26.11.2020

Accepted:

25.12.2020

Close metadata

References:

Vyberg M, Nielsen S, Røge R, Sheppard B, Ranger-Moore J, Walk E, Gartemann J, Rohr UP, Teichgräber V. Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests. BMC Health Serv Res. 2015;15:352. https://doi.org/10.1186/s12913-015-1018-6
Di Leo A, Dowsett M, Horten B, Penault-Llorca F. Current status of HER2 testing. Oncology. 2002;63(suppl 1):25-32.
Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology. Updated UK Recommendations for HER2 assessment in breast cancer. al. J Clin Pathol. 2015;68(2):93-99. https://doi.org/10.1136/jclinpath-2014-202571
Vyberg M, Nielsen S. Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC). Virchows Arch. 2015;468(1):19-29. https://doi.org/10.1007/s00428-015-1829-1
Raundy TsKKNN. Retrieved 22 October 2020. (In Russ.). https://ihccqc.rmapo.ru/raundy/
Torlakovic EE, Nielsen S, Vyberg M, Taylor CR. Getting controls under control: the time is now for immunohistochemistry. J Clin Pathol. 2015;68(11):879-882. https://doi.org/10.1136/jclinpath-2014-202705
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412-424. https://doi.org/10.5306/wjco.v5.i3.412
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. Retrieved 22 October 2020. https://www.jcancer.org/v07p1281.htm
Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480-487. https://doi.org/10.1093/annonc/mdv611
Frank GA, Zavalishina LE, Andreeva YuYu, eds. Rak molochnoi zhelezy. Morfologicheskaya diagnostika i genetika. Prakticheskoe rukovodstvo dlya vrachei. 2nded. M.: Prakticheskaya meditsina; 2021. (In Russ.).
Foley NM, Coll JM, Lowery AJ, Hynes SO, Kerin MJ, Sheehan M, Brodie C, Sweeney KJ. Re-appraisal of estrogen receptor negative/progesterone receptor positive (ER−/PR+) breast cancer phenotype: true subtype or technical artefact? Pathol Oncol Res. 2018;24(4):881-884. https://doi.org/10.1007/s12253-017-0304-5
Kushnarev VA, Smirnova VO, Chirskii VS, Timofeev IV, Artem’eva AS, Kudaibergenova AG, Krivorot’ko PV, Semiglazova TYu, Semiglazov VF. A digital quantitative analysis of the expression of estrogen and progesterone receptors (ER/PgR) in invasive breast carcinomas in whole sections. Vestnik of the Smolensk State Medicail Academy=Vestnik Smolenskoy gosudarstvennoy medicinskoy akademii. 2020;19(2):113-118. (In Russ.). https://doi.org/10.37903/vsgma.2020:2.15
Sazonov SV. Features of the external quality control system for immunohistochemical diagnosis of breast cancer in the Ural Federal District (reference) in 2014. Bulletin of Ural Medical Academic Science=Vestnik Ural’skoy meditsinskoy akademicheskoy nauki. 2015;(4):15-19. (In Russ.).